Bio-Techne (TECH) Set to Release Quarterly Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) is expected to issue its Q1 2027 results before the market opens on Wednesday, November 4th. Analysts expect Bio-Techne to announce earnings of $0.44 per share and revenue of $292.60 million for the quarter. Investors may visit the company’s upcoming Q1 2027 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.52. The firm had revenue of $321.19 million during the quarter, compared to analysts’ expectations of $314.63 million. During the same quarter in the previous year, the firm posted $0.53 EPS. Bio-Techne’s revenue was up 1.3% compared to the same quarter last year. On average, analysts expect Bio-Techne to post $1.70 EPS for the current fiscal year and $1.91 EPS for the next fiscal year.

Bio-Techne Price Performance

TECH stock opened at $72.60 on Wednesday. Bio-Techne has a 1 year low of $43.19 and a 1 year high of $72.75. The firm has a 50-day moving average of $72.43 and a 200 day moving average of $63.17.

Bio-Techne Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 4th. Shareholders of record on Monday, August 24th were given a $0.65 dividend. This is a positive change from Bio-Techne’s previous quarterly dividend of $0.08. The ex-dividend date of this dividend was Monday, August 24th. This represents a $2.60 dividend on an annualized basis and a yield of 3.6%.

Analysts Set New Price Targets

TECH has been the subject of a number of research reports. Zacks Research raised shares of Bio-Techne from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 25th. Wells Fargo & Company cut Bio-Techne from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $62.00 to $73.00 in a report on Thursday, August 13th. Benchmark reaffirmed a “hold” rating on shares of Bio-Techne in a research note on Wednesday, August 19th. Argus cut Bio-Techne from a “strong-buy” rating to a “strong sell” rating in a research note on Monday. Finally, Royal Bank Of Canada cut shares of Bio-Techne from an “outperform” rating to a “sector perform” rating and boosted their price objective for the company from $62.00 to $73.00 in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $68.92.

About Bio-Techne

Bio-Techne Corporation is a life sciences company that develops and supplies research and diagnostic products for biotechnology, pharmaceutical, academic, clinical and other laboratory customers. The company supports biological research, drug discovery and development, and diagnostic testing through a portfolio of reagents, instruments and analytical technologies.

Its products include proteins, antibodies, immunoassays, flow cytometry reagents, molecular biology tools and cell culture materials.